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Abstract
Gadoxetic acid improves detection and characterization 
of focal liver lesions in cirrhotic patients and can 
estimate liver function in patients undergoing liver 
resection. The purpose of this article is to describe the 
optimal gadoxetic acid study protocol for the liver, the 
unique characteristics of gadoxetic acid, the differences 
between gadoxetic acid and extra-cellular gadolium 
chelates, and the differences in phases of enhancement 
between cirrhotic and normal liver using gadoxetic 
acid. We also discuss how to obtain and recognize an 
adequate hepatobiliary phase.
Key words: Hepatobiliary contrast materials; Gadoxetic 
acid; Cirrhosis; Magnetic resonance imaging; Liver
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Core tip: Hepatobiliary contrast materials improve 
detection and characterization of focal liver lesions 
in cirrhotic patients and can measure liver function. 
Familiarity with unique characteristics of gadoxetic acid 
is crucial to achieve an optimal magnetic resonance 
examination of the liver. In this review, we discuss 
the protocol for gadoxetic acid enhanced magnetic 
resonance imaging of the liver and describe differences 
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between gadoxetic acid and extra-cellular contrast 
materials.
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INTRODUCTION
Several studies have demonstrated the added value 
of hepatobiliary contrast agents in the detection and 
characterization of focal liver lesions in cirrhotic patients 
compared with extra-cellular gadolinium chelates and 
contrast enhanced computed tomography (CT)[1-4]. 
Hepatobiliary contrast agents are first distributed in the 
extracellular fluid compartment, subsequently taken 
up by functioning hepatocytes, and then excreted into 
the biliary system[5,6]. Thus, hepatobiliary contrast 
agents can differentiate lesions that contain functioning 
hepatocytes, such as regenerative nodules and most 
dysplastic nodules, from hepatocellular lesions without 
functioning hepatocytes, such as most hepatocellular 
carcinomas (HCCs) and nonhepatocellular lesions, 
such as cyst, hemangioma, cholangiocarcinoma, 
metastases[7]. 
There are two commercially available hepatobiliary 
contrast agents: gadolinium ethoxybenzyl diethy-
lenetriamine pentaacetic acid (gadoxetic acid; 
Eovist/Primovist; Bayer-Healthcare, Leverkusen, 
Germany) and gadobenate dimeglumine (Multihance, 
Bracco, Italy). Both of them allow evaluation of lesion 
vascularity and hepatobiliary function. However, 
approximately 50% of the injected dose of gadoxetic 
acid is eliminated by functioning hepatocytes, while only 
3%-5% gadobenate dimeglumine undergoes the same 
pathway of excretion[5,6]. Therefore, using gadoxetic 
acid, higher hepatobiliary uptake results in greater 
enhancement of liver parenchyma[8]. 
Another unique feature of gadoxetic acid is the 
rapid hepatocellular uptake (starting at approximately 
90 s after injection)[1], which results in an overlap 
between extracellular and hepatobiliary phases (the so-
called “transitional phase”). Rapid uptake of gadoxetic 
acid allows acquisition of the hepatobiliary phase 
at 20 min after contrast injection[1]. Hepatocellular 
uptake of gadobenate dimeglumine starts no sooner 
than 40 min after contrast injection[5]. Therefore, 
the extracellular phase of gadobenate dimeglumine 
is “pure” (it shows no overlap with the hepatobiliary 
phase, similar to what can be obtained with any 
extracellular contrast agent), and the hepatobiliary 
phase is typically acquired 60-180 min after contrast 
injection[9]. Thus, with gadobenate dimeglumine, 
dynamic and hepatobiliary images are acquired in two 
separate sessions, increasing examination time and 
patient discomfort. For these reasons, gadoxetic acid 
is generally preferred over gadobenate dimeglumine 
when acquisition of hepatobiliary phase is deemed 
necessary for the management of patients. The main 
disadvantage of liver magnetic resonance imaging 
(MRI) with gadoxetic acid is the contrast cost: the 
purchase price of gadoxetic acid is approximately 
twice that of gadobenate dimeglumine. As MRI 
reimbursements in the public sector are fixed, many 
institutions use gadobenate dimeglumine instead of 
gadoxetic acid for economic reasons. 
In this review, we describe the optimal MRI study 
protocol of the liver and the differences in phases of 
enhancement between cirrhotic and normal liver using 
gadoxetic acid. We also illustrate the differences in 
phases of enhancement between gadoxetic acid and 
extracellular contrast agents and discuss how to obtain 
and recognize an adequate hepatobiliary phase.
WHY GADOXETIC ACID IN THE 
CIRRHOTIC LIVER
The need for an accurate detection and characterization 
of HCC represents the main reason for the increasing 
use of gadoxetic acid in cirrhotic patients[10-12]. The 
ability to detect HCC with gadoxetic acid depends 
on the differences in hepatocellular contrast uptake 
between HCC and the surrounding liver[4]. On 
hepatobiliary phase, HCCs are typically hypointense 
due to the absence of functioning hepatocytes, while 
the liver parenchyma enhances due to hepatocellular 
uptake of gadoxetic acid. Consequently, HCC to liver 
contrast and HCC detection rate are increased[4]. 
Hepatobiliary phase hypointensity also helps 
differentiate HCCs from dysplastic and regenerative 
nodules. Since hepatocellular uptake of gadoxetic acid 
decreases during hepatocarcinogenesis, hepatobiliary 
phase hypointensity suggests a diagnosis of HCC 
over that of dysplastic and regenerative nodules, 
which are typically iso- or hyperintense[13-16]. Typical 
imaging appearance of HCC includes moderate arterial 
enhancement and venous wash-out[17]. Using these 
criteria, however, several small HCCs can be missed 
because of absence of venous wash-out or, more 
rarely, arterial enhancement[18]. The hypointensity on 
hepatobiliary phase helps to correctly characterize 
small HCCs[13-16,19]. Hepatobiliary phase hypointensity, 
however, is not specific for the diagnosis of HCC because 
it can be found in any non-hepatocyte containing 
lesion (e.g., hemangiomas, cholangiocarcinomas, 
metastases)[20]. 
Another application of gadoxetic acid is the pre-
operative evaluation of patients scheduled for liver 
resection[21,22]. Recent studies have reported that 
quantitative analysis of hepatocellular uptake of 
gadoxetic acid can be used to estimate liver function 
and to predict the risk of liver failure after major hepatic 
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resection[21,22]. Hepatocellular uptake of gadoxetic acid 
correlates with indocyanine green clearance and uptake 
of radiopharmaceutical agents[22,23]. The advantages 
of gadoxetic acid over traditional methods, such as 
indocyanine green clearance and hepatic scintigraphy 
with radiopharmaceutical agents, include anatomic 
resolution (i.e., liver function can be evaluated at 
segmental or subsegmental level) and the absence of 
ionizing radiation[24].
OPTIMAL STUDY PROTOCOL OF THE 
LIVER 
An ideal MRI liver protocol should evaluate both liver 
parenchyma and vessels and should aid in detection 
and characterization of hepatic lesions. Typically, MRI 
liver protocol includes T2-weighted turbo or fast spin-
echo (with and without fat saturation) sequences, 
gradient-recalled echo (GRE) T1-weighted in- and 
opposed-phase sequence, diffusion-weighted (DW) 
sequence, and contrast-enhanced three-dimensional 
T1-weighted GRE sequence with fat suppression. 
Field-strength magnets of 1.5 Tesla or greater are 
recommended to obtain high-quality liver imaging[25]. 
Contrast administration should be performed through a 
power injector. The use of a saline solution is strongly 
recommended because it reduces the dose of contrast 
material remaining in the dead space (e.g., the 
brachial vein) and shortens the arrival time of contrast 
material in the hepatic arteries[10]. Contrast enhanced 
images are obtained on vascular, transitional, and 
hepatobiliary phases[26]. Vascular phases include the 
late hepatic arterial and portal venous phases[26]. 
Late hepatic arterial phase is crucial to detect and 
characterize hypervascular lesions[27]. Demonstration 
of moderate enhancement of intrahepatic portal veins, 
slight enhancement of liver parenchyma, and no 
enhancement of hepatic veins indicate an appropriate 
timing[28]. Achieving an adequate arterial phase 
with gadoxetic acid is more challenging than with 
conventional extra-cellular contrast materials. Due 
to the higher T1-relaxivity, gadoxetic acid has one-
half lower contrast volume and one fourth lower Gd-
content per kg than those of conventional extra-cellular 
contrast materials[29]. Thus, gadoxetic acid injection 
duration and time to peak aortic enhancement are 
shorter than those of conventional extra-cellular 
contrast materials[29]. In addition, the administration 
of gadoxetic acid has been associated with acute 
self-limited dyspnea, and consequent severe motion 
artifacts[30]. By definition, acute self-limited dyspnea 
is limited to the hepatic arterial phase images, and 
respiratory motion artifacts are absent in other 
sequences[30]. The exact cause remains unknown. 
A relationship between higher gadoxetic acid doses 
and chronic obstructive pulmonary disease has been 
reported[31]. Because the dyspnea is transient (10-20 s), 
a potential solution in order to overcome the artifacts 
is to acquire more than one arterial phase image. This 
approach is advantageous because: (1) acquisition of 
a greater number of phases increases the likelihood 
to obtain at least one diagnostic arterial phase image; 
and (2) reducing the acquisition time of each phase 
minimizes the opportunity for motion[30]. 
There are methods for achieving an optimal an 
optimal hepatic arterial phase. The most frequently 
used is a fixed delay (approximately 25-30 s) between 
the start of contrast injection and data acquisition. 
This method, however, is often inadequate because 
it does not take into account injection- or patient-
related factors (e.g., cardiac output) that influence 
circulation time. Indeed, arterial phase images are 
frequently obtained either too early (i.e., before portal 
venous enhancement) or too late (i.e., when contrast 
is already in the hepatic veins)[32]. Another option is 
the test bolus technique, in which a small test bolus 
(1-2 mL) of contrast material is injected to calculate 
contrast material arrival time. Although this technique 
is effective with extra-cellular contrast materials, 
it is not recommended in gadoxetic acid enhanced 
MRI because hepatocellular uptake of the bolus can 
increase liver signal intensity, and the removal of 
bolus volume from the pre-filled syringe can leave 
insufficient contrast to administer during the dynamic 
phases of the study. The use of a fluoroscopic system 
(MR SmartPrep, GE Medical Systems, Milwaukee, WI, 
United States; CARE Bolus, Siemens Medical Solutions, 
Erlangen, Germany; Bolus-Track, Philips Medical 
Systems, Best, The Netherlands) is preferable[10]. This 
technique is based on real-time monitoring of the bolus 
arrival at the level of the vessel of interest (typically 
the suprarenal abdominal aorta) with a 2D fluoroscopic 
sequence. Arterial phase acquisition can be started 
manually or automatically with a trigger threshold. 
The optimal scan delay for late hepatic arterial phase 
is 15-20 s after the peak aortic enhancement, which 
corresponds to the time necessary to synchronize the 
arrival of contrast material in the main portal vein with 
central k-space filling[26].  
The injection of contrast material breaks k-space 
homogeneity and can cause truncation artifacts[33]. 
These artifacts appear as dark or bright lines at 
interfaces between high and low signal intensity 
structures (e.g., enhanced arteries and surrounding 
liver parenchyma) and alter anatomic details of 
structures[34]. Several methods of minimizing truncation 
artifacts truncation artifacts have been proposed. One 
option is to use a larger volume of contrast material 
by diluting gadoxetic acid with saline[33]. Alternatively, 
a slow (1 mL/s) injection rate, which results in natural 
dilution of the contrast in the vascular space, can be 
used[35]. In addition, to increase k-space homogeneity, 
the larger contrast volume provides a wider temporal 
window of hepatic arterial phase. Tamada et al[36] 
compared arterial phase images obtained with 
three different techniques: diluted gadoxetic acid 
administered at conventional rate of 3 mL/s; undiluted 
gadoxetic acid administered at conventional rate of 3 
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hepatocytes through a canalicular multispecific organic 
anion transporting polypeptide 1B3 (OATP1B3) as 
early as 90 s after contrast injection, but this process 
takes several minutes before all contrast is taken up by 
hepatocytes. Thus, gadoxetic acid “transitates” from 
interstitial space to intracellular space. That is why we 
refer to this phase as the transitional phase, indicating 
the transition of gadoxetic acid from the extra-cellular 
space to the hepatocellular space[37]. In contrast, 
extra-cellular contrast materials are equally distributed 
between vascular spaces and interstitial spaces. 
Hepatocellular uptake of gadoxetic acid explains higher 
signal intensity of liver parenchyma with gadoxetic acid 
than with extracellular contrast materials[39]. Earlier 
elimination of gadoxetic acid from the vessels leads to 
earlier de-enhancement and, therefore, lower signal 
mL/s; and undiluted gadoxetic acid administered at a 
rate of 1 mL/s. They concluded that the injection rate 
of 1 mL/s with undiluted gadoxetic acid was preferable 
to the other two methods[37]. Portal venous phase is 
acquired 50-70 s after gadoxetic acid injection. On 
portal venous phase, the liver parenchyma shows 
intense enhancement, and the portal and hepatic 
veins are fully and maximally enhanced[38] The interval 
time (2-5 min after gadoxetic acid injection) between 
perfusion phase and hepatobiliary phase is termed 
“transitional phase”, and, therefore, should not be 
confused with or referred to as the equilibrium phase 
that is typically obtained at the same time delay with 
extracellular contrast agents[37] (Figures 1 and 2). The 
transitional phase is obtained 3 min after the start of 
contrast injection[26]. Gadoxetic acid shows uptake by 
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PRE Vascular phase Transitional phase Hepatobiliary phase
Figure 1  Gadoxetic acid contrast-enhanced magnetic resonance images obtained in a 46-year-old woman with normal liver. Contrast-enhanced magnetic 
resonance images show a stepwise intensity increase of the liver parenchyma from the hepatic arterial phase to hepatobiliary phase. On hepatic arterial and portal 
venous phases (vascular phase), the intrahepatic vessels show intense and homogeneous enhancement. On 3 min late and 5 min late phases (transitional phase), 
the intrahepatic vessels (open arrows) show isointensity to the liver, indicating the transition of gadoxetic acid from the extra-cellular spaces to the hepatocellular-
spaces. On 10 min and 20 min phase (hepatobiliary phase), the intrahepatic vessels show hypointensity to the liver, while the bile ducts (arrows) show hyperintensity; 
these findings indicate an adequate hepatobiliary phase. Also note kidney hypointensity to the liver, which indicates normal hepatobiliary elimination of gadoxetic acid 
and adequate hepatobiliary phase. PRE: Precontrast; HAP: Late hepatic arterial phase; PVP: Portal venous phase. 
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Figure 2  Intraindividual differences in hepatic enhancement in cirrhotic liver between extra-cellular contrast agent (top row) and gadoxetic acid 
(bottom row) in a 69-year-old woman with hepatitis C virus-related cirrhosis. On contrast-enhanced magnetic resonance (MR) images obtained with an extra-
cellular agent liver enhancement peaks on portal venous phase and then slightly decreases. On contrast-enhanced MR images obtained with gadoxetic acid, liver 
enhancement shows a stepwise increase from the hepatic arterial phase to the 20 min phase. Vascular enhancement is more prolonged with extra-cellular agent than 
with gadoxetic acid, indicating a slower vascular elimination. On 10 min, the intrahepatic vessels (black arrow) show slight hypointensity to the liver, and the bile ducts 
are not opacified. These findings indicate hepatic dysfunction and a prolonged transitional phase. Also, note a wedge shaped enhancing area in the hepatic arterial 
phase (white arrow), with lack of washout on portal venous phase and isointensity on hepatobiliary phase, due to arterioportal shunt. PRE: Precontrast; HAP: Late 
hepatic arterial phase; PVP: Portal venous phase. 
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intensity of intrahepatic vessels with gadoxetic acid 
than with extra-cellular contrast materials (Figure 2)[39]. 
Hepatobiliary phase is acquired 10-20 min after 
the start of contrast injection. Since the injection of 
gadoxetic acid does not compromise tissue contrast on 
T2-weighted images and diffusion-weighted images, 
these sequences can be acquired in the interval 
between the 3 min phase and the hepatobiliary phase, 
thus reducing the total examination time[40-42]. DW 
images can help to differentiate hypovascular HCC 
from high-grade dysplastic nodules and can predict 
the progression of hypovascular hypointense nodules 
on hepatobiliary phase into hypervascular HCC[43,44]. 
That is, hyperintensity on high-b-value DW images 
suggests a diagnosis of HCC and is strongly associated 
with progression of hypovascular nodules into 
hypervascular HCC[43,44]. The adjunct of DW images, 
however, does not significantly improve the diagnostic 
accuracy of MRI with hepatobiliary contrast materials 
in the detection of HCC[45,46]. Most small HCCs are 
imperceptible on DW images because they have 
cellular density and microscopic architecture relatively 
similar to that of surrounding cirrhotic liver[46]. 
DIFFERENCES IN PHASES OF 
ENHANCEMENT BETWEEN GADOXETIC 
ACID AND EXTRA-CELLULAR CONTRAST 
MATERIALS 
Although gadoxetic acid allows dynamic imaging during 
the hepatic arterial, portal venous, and 3 min phases, 
some enhancement characteristics are different from 
those of extracellular contrast materials[1,39] (Figure 2). 
Gadoxetic acid shows a biphasic enhancement pattern 
in the liver[1]. The first phase (arterial + portal venous) 
is due to distribution in the vascular compartment. 
The second phase is due to hepatocellular uptake of 
gadoxetic acid by the canalicular multispecific OATP1B3 
and starts 90 s after injection[1]. Extra-cellular con-
trast materials distribute in the extracellular fluid 
compartments, and, as the name implies, they are not 
taken up by the hepatocytes[1]. Liver enhancement 
peaks on portal venous phase and then decreases[39]. 
Vascular enhancement is higher and longer with 
extracellular contrast materials than with gadoxetic 
acid[39]. It has been reported that, on hepatic arterial 
phase, aorta and liver parenchymal enhancement is 
weaker[39]. Since most HCCs are hypervascular, this 
can influence their detection and characterization[1,39]. 
On portal venous phase, the signal intensity of liver 
parenchyma is comparable between gadoxetic acid 
and extra-cellular contrast materials, but the signal 
intensity of portal vein is lower with gadoxetic acid 
than with extra-cellular contrast materials[39]. Thus, 
the evaluation of portal and hepatic veins can be 
suboptimal with gadoxetic acid[12]. Since HCC invasion 
into portal or hepatic vein and portal vein thrombosis 
influence treatment options and can preclude surgical 
resection and liver transplantation, vascular evaluation 
can reduce the advantages of gadoxetic acid. 
DIFFERENCES IN PHASES OF 
ENHANCEMENT BETWEEN CIRRHOTIC 
AND NORMAL LIVER WITH GADOXETIC 
ACID 
Cirrhosis is characterized pathologically by distortion 
of hepatic architecture due to marked bridging 
hepatic fibrosis and regenerative nodule formation[47]. 
The number of normal hepatocytes is reduced, and 
biliary excretion is impaired[34,48]. Cirrhosis alters 
liver perfusion with a reduction in portal inflow and a 
compensatory increase of arterial inflow[11]. Thus, on 
hepatic arterial phase, liver enhancement is higher in 
cirrhotic patients than in normal-liver patients[49]. On 
portal venous phase, however, liver enhancement is 
superimposable in cirrhotic patients and normal-liver 
patients[49]. At 3 min and in the hepatobiliary phases, 
liver enhancement is higher in normal patients than 
in cirrhotic patients and shows an inverse correlation 
with the severity of cirrhosis[49]. This is because 
hepatic fibrosis and the reduction in the number of 
functioning hepatocytes decrease the hepatocellular 
uptake of gadoxetic acid[49]. Pharmacokinetic analysis 
demonstrated that liver signal intensity shows a 
stepwise increase from the hepatic arterial phase 
to the hepatobiliary phase in patients with normal 
liver and in patients with Child-Pugh class A and B 
cirrhosis (Figure 1); on the other hand it does not 
significantly change from portal venous phase to 20 
min hepatobiliary phase in patients with Child-Pugh 
class C cirrhosis[49] (Figure 3). The consequence is that 
oftentimes, at 20 min, the vessels will not be “dark” 
enough in patients with Child-Pugh class C cirrhosis, 
resulting in a suboptimal hepatobiliary phase. Thus, 
in our practice, acquisition of hepatobiliary phase 
beyond the conventional 20 min delay may be useful 
in patients with impaired hepatic function in order to 
allow the hepatocytes more time to take up contrast 
from the extracellular space[50,51]. Conversely, in 
normal-liver patients, a hepatobiliary delay of 10 min 
after gadoxetic acid injection is sufficient[52]. Unlike 
normal liver, cirrhotic liver can show heterogeneous 
enhancement on the hepatobiliary phase, which can 
further complicate the detection and characterization 
of hepatic nodules[49]. The heterogeneity directly 
correlates with Child-Pugh class[49]. Enhancement 
of biliary tree is delayed in patients with cirrhosis 
compared with normal-liver patients[48]. 
Tschirch et al[52] compared the visualization of 
biliary tree between cirrhotic patients and normal-liver 
patients and found that 16/40 (40%) cirrhotic patients 
showed sufficient visualization of the biliary tree within 
30 min of injection, and 21/40 (53%) cirrhotic patients 
showed sufficient visualization of the biliary tree within 
180 min of injection. In contrast, in their series, all 
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normal-liver patients showed sufficient visualization of 
the biliary tree within 30 min of injection[48]. 
ADEQUACY OF HEPATOBILIARY PHASE 
In patients with normal hepatic function, gadoxetic 
acid is equally eliminated by biliary excretion and 
glomerular filtration[6]. Impaired hepatic function 
results in a compensatory increase of renal elimination 
and more prolonged plasma half-life of gadoxetic acid 
in cirrhotic patients than in normal-liver patients[36]. 
The consequence is typically a decrease of contrast 
between liver parenchyma and portal vein[53]. Visual 
evaluation of the signal intensity of the liver relative to 
the portal vein or kidney can help radiologists assess 
adequacy of the hepatobiliary phase[34,38]. Specifically, 
brighter signal intensity of the liver parenchyma 
compared with the portal vein and kidney indicates 
an adequate hepatobiliary phase, while persistent 
contrast within the portal vein and brighter or equal 
signal intensity of the kidney compared with the liver 
parenchyma indicates an inadequate hepatobiliary 
phase[36,39] (Figures 3 and 4). Opacification of the 
biliary tree shows no correlation with the severity 
of cirrhosis and cannot be used alone to evaluate 
adequacy of the hepatobiliary phase[48] (Figure 4).
The uptake of gadoxetic acid does not depend only 
on the hepatic function but also on the hepatic blood 
flow[33]. Motosugi et al[33] reported that most patients 
with Child Pugh Class A cirrhosis and inadequate 
hepatobiliary phase had considerable arterial-portal 
and portal-systemic shunts. The shunts decrease the 
hepatic blood flow and hepatic retention of gadoxetic 
acid[33]. Other causes of reduced hepatobiliary phase 
enhancement include severe steatosis (Figure 5), 
hepatic fibrosis, and iron overload[54-57]. An inade-
quate hepatobiliary phase may impair detection 
and characterization of focal liver lesions because 
the contrast between focal liver lesions and the liver 
parenchyma is reduced[58]. These patients should be 
evaluated with alternative modalities, such as contrast-
enhanced CT and contrast-enhanced ultrasound, in 
order to avoid misdiagnosis. To date, however, no liver 
function test can predict whether the hepatobiliary 
phase result will be adequate. 
Recent studies have demonstrated that increasing 
the flip-angle from 10°-15° to 30°-40° can improve 
detection and conspicuity of focal hepatic lesion, 
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PRE HAP PVP 3-min 5-min 10-min 20-min
Figure 3  Gadoxetic acid contrast-enhanced magnetic resonance images obtained in a 57-year-old man with Child-Pugh C hepatitis C virus-related 
cirrhosis. Contrast-enhanced magnetic resonance images show slight decrease of liver enhancement after the portal venous phase. On hepatic arterial and portal 
venous phases, the intrahepatic vessels show intense and homogeneous enhancement, which persists on 3 min, 5 min, and 10 min phase. On 20 min phase, the 
intrahepatic vessels show isointensity to the liver. Prolonged retention of the contrast in intrahepatic vessels indicates impaired hepatic function and an inadequate 
hepatobiliary phase. Twenty minutes phase corresponds in this case to the transitional phase observed in normal liver patient due to prolonged retention of gadoxetic 
acid in intrahepatic vessels. Also, note that the kidney shows isointensity to the liver on 10 min and 20 min phases, indicating a compensatory increase of renal 
elimination of gadoxetic acid and an inadequate hepatobiliary phase. PRE: Precontrast; HAP: Late hepatic arterial phase; PVP: Portal venous phase. 
Figure 4  Twenty-minute hepatobiliary phase gadoxetic acid enhanced magnetic resonance imaging obtained in a 67-year-old man with Child-Pugh class 
A hepatitis C virus-related cirrhosis (A) and in a 67-year-old woman with Child-Pugh class B hepatitis C virus-related cirrhosis (B). A: The liver shows high 
signal intensity compared with the portal vein (arrowhead), which shows hypointensity; B: The liver shows relative high signal intensity compared with the portal vein 
(arrowhead), which shows “less” hypointensity if compared with A. Visual comparison of signal intensity of the liver relative to the portal vein can be used to evaluate 
adequacy of hepatobiliary phase. Enhancement of bile ducts, noted in both A and B (arrows), cannot be used alone to indicate adequacy of hepatobiliary phase.
BA
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particularly of small lesions[44-46]. Larger flip angle 
maximizes T1-contrast and results in better diffe-
rentiation between tissues with short T1-relaxation 
times, such as liver parenchyma with gadoxetic acid 
uptake and tissues with long T1-relaxation times, such 
as lesions without functioning hepatocytes[59-61]. Larger 
flip angle, however, increases specific absorption rate 
(SAR) in patient tissue[59].
CONCLUSION
Gadoxetic acid enhanced liver MRI is emerging as 
a powerful tool in the diagnostic workup of cirrhotic 
patients and provides unique information related to 
lesion vascularity and hepatobiliary function. Use of 
gadoxetic acid improves detection and characterization 
of focal liver lesions, and hepatocellular uptake can be 
used as a measure of liver function. Thus, radiologists 
involved in liver imaging need to be familiar with the 
state-of-art MRI study protocol of the liver and the 
unique characteristics of gadoxetic acid. 
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